Main Menu
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Carcinoid Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Solid Tumors Clinical Trials
- Thyroid Clinical Trials
- Uterine Clinical Trials
- St. Luke's
- About Oncology Trials
- Glossary of Terms
- St. Luke's
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- St. Luke's
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- St. Luke's
- GME Data & Outcomes
- Post Doctoral Research
- Research Volunteer Program
- Institutional Review Board
- St. Luke's
- 1-866-STLUKES
EKOS KNOCOUT BTG
EKOS KNOCOUT BTG
Retrospective and prospective international EKoSoNic® registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism (KNOCOUT PE)
Physician & Study Coordinator
Physician

Prashant Patel, MD
Close
Synopsis
Synopsis: The purpose of this clinical Registry is to understand how doctors are currently treating lung artery clots with clot-dissolving drugs and EKOS. Data collected for the Registry will focus on length of treatment, amount of drug used and how your health and quality of life are impacted over time by the treatment.
Close
Inclusion Criteria
- Retrospective Inclusion Criteria:
- Treated with APT procedure between January 1, 2014 and one year prior to site activation
- RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
- PE symptom duration ≤ 14 days
- Troponin elevation
- Prospective Inclusion Criteria:
- Male or female ≥ 18 years of age and ≤ 80 years of age
- RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
- PE symptom duration ≤ 14 days
- Troponin elevation
- Signed informed consent obtained from subject or legally authorized representative
- Investigator has selected the EKOS device to treat patient with massive or submassive pulmonary embolism
Close
Exclusion Criteria
- Retrospective Exclusion Criteria:
- Enrollment into the OPTALYSE PE study
- Prospective Exclusion Criteria:
- Clinician deems the subject high-risk for catastrophic bleeding
- Life expectancy < one year
Close
Research
Interested in a
Clinical Trial?